Aronora, Inc.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Holding
- Established
- 2007-01-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.aronorabio.com
Clinical Trials
4
Active:0
Completed:4
Trial Phases
2 Phases
Phase 1:2
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials
Phase 1
2 (50.0%)Phase 2
2 (50.0%)Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis
Phase 2
Completed
- Conditions
- End Stage Renal DiseaseThrombosis
- Interventions
- Drug: AB002 Dose 1Drug: AB002 Dose 2Drug: placebo
- First Posted Date
- 2019-05-28
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Aronora, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT03963895
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Safety and Efficacy Study of AB023 (Xisomab 3G3) in End Stage Renal Disease Patients on Chronic Hemodialysis
Phase 2
Completed
- Conditions
- End Stage Renal DiseaseThrombosis
- Interventions
- Drug: AB023-Dose 2Drug: placeboDrug: AB023- Dose 1
- First Posted Date
- 2018-08-02
- Last Posted Date
- 2024-03-07
- Lead Sponsor
- Aronora, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT03612856
- Locations
- 🇺🇸
Orlando Clinical Research Center, Orlando, Florida, United States
Safety and Tolerability Study of E-WE Thrombin in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Thrombosis
- Interventions
- Drug: E-WE Thrombin- Dose 1Drug: E-WE Thrombin- Dose 2Drug: E-WE Thrombin- Dose 3Drug: E-WE Thrombin- Dose 4Other: Placebo
- First Posted Date
- 2018-03-05
- Last Posted Date
- 2019-10-29
- Lead Sponsor
- Aronora, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03453060
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
Safety and Tolerability Study of Xisomab 3G3 in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Thrombosis
- Interventions
- Drug: xisomab 3G3- Dose 4Drug: xisomab 3G3-Dose 2Other: PlaceboDrug: xisomab 3G3- Dose 1Drug: xisomab 3G3-Dose 3
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2019-06-05
- Lead Sponsor
- Aronora, Inc.
- Target Recruit Count
- 21
- Registration Number
- NCT03097341
- Locations
- 🇺🇸
Celerion, Tempe, Arizona, United States
News
No news found